SystImmune Receives FDA Clearance of IND Application for Bispecific Antibody SI-B037
On Sept. 23, 2026, SystImmune announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New…
-
-
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases for $2.875 billion in cash
On Aug. 31, 2026, Eli Lilly and Merida Biosciences, a biotechnology company advancing a new class of precision…
-
FDA approves Johnson & Johnson’s IMAAVY® as first-ever treatment for warm autoimmune hemolytic anemia, a landmark advancement
On Aug. 24, 2026, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY®…
-
Nanoparticles sneak antibodies into cells to inhibit cancer, inflammation
On Jun. 23. 2026, scientists at Cornell University announce discovering a delivery system that uses lipid nanoparticles to…
-
Incyte to Acquire Vega Therapeutics, Subsidiary of Star Therapeutics, for $1.25 billion, Expanding its Hematology Portfolio into Bleeding Disorders
On Jun. 8, 2026, Incyte announced it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned…
-
Gilead to Acquire Tubulis for $5 Billion to Further Strengthen Oncology Pipeline
On Apr. 7, 2026, Gilead Sciences announced it has entered into a definitive agreement to acquire Tubulis, a…
-
Scientists develop first-of-its-kind antibody to block Epstein Barr virus
On Feb. 17, 2026, Fred Hutch Cancer Center scientists announced reaching a crucial milestone in blocking Epstein Barr…
-
Some antibodies outmaneuver germs from sticking to cells
On Jan. 6, 2026, a study led by University of Washington School of Medicine researchers uncovered several new…
-
Space Station Research Supports New FDA-Approved Cancer Therapy
On Dec. 18, 2025, the National Aeronautics and Space Administration (NASA) announced it has opened the International Space…
-
Lilly announces plans to build $5 billion manufacturing facility in Virginia
On Sept. 16, 2025, Eli Lilly announced that it plans to build a $5 billion manufacturing facility just…
-
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
On Mar. 3, 2025, Revvity announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support…
-
Agriculture | Chemistry | Diagnostics | HIV | Infectious Disease | Neurology | NIH | Non-Profit Research | Therapeutics
HIV vaccines can lead to Chain Reaction of antibodies against antibodies
On Jan. 17, 2025, scientists from Scripps Research Institute reported finding that some HIV vaccination can lead to…
-
Study found no birth defect risk from tetracycline use during first trimester of pregnancy
On Nov. 15, 2024, a team led by researchers from Sweden’s Karolinska Institutet reported study results that showed…
-
Nasal Swab Tests Predict COVID-19 Disease Severity, Study Finds
On Nov. 6, 2024, researchers from Emory University, in collaboration with scientists at Gladstone Institutes and University of…
-
CDC reported little to no immunity to H5N1 avian flu virus in Americans
On Jun. 14, 2024 the Centers for Disease Control and Prevention (CDC) reported data from this study suggested…
-
Repeat COVID-19 vaccinations elicit antibodies that neutralize variants, other viruses
On May 17, 2024, researchers at Washington University School of Medicine in St. Louis announced a study had…
-
Study suggested staying current with COVID-19 vaccinations helped combat emerging variants
On Apr. 12, 2024, Oregon Health Sciences University (OHSU) announced research that shows using live SARS-CoV-2 virus revealed…
-
New antibodies target ‘Dark Side’ of influenza virus protein
On Mar. 1, 2024, researchers at the National Institutes of Health (NIH) announced they had identified antibodies targeting…
-
Vir Biotechnology awarded BARDA funding to support development of antibody platform technologies for global infectious disease threats
On Oct. 3, 2023, Vir Biotechnology announced that the Biomedical Advanced Research and Development Authority (BARDA), part of…
-
Moderna clinical trial data confirmed updated Covid-19 vaccine generated strong immune response against BA.2.86 variant
On Sept. 6, 2023, Moderna announced that clinical trial data from its research assay confirmed its updated COVID-19…
-
COVID-19 vaccination and boosting during pregnancy benefits pregnant women and newborns
On Aug. 11, 2023, a study funded by the National Institute of Allergy and Infectious Diseases (NIAID) reported…
-
University of Illinois Urbana-Champaign team developed all-species coronavirus test
On Jul. 6, 2023, University of Illinois Urbana-Champaign researchers reported they can detect exposure to the SARS-CoV-2 virus…
-
Biotechnology | Diagnostics | Disease | FDA | Rare Disease | Therapeutics
U.S. FDA approved BioMarin’s ROCTAVIAN, the first and only gene therapy for adults with severe hemophilia A
On Jun. 29, 2023, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy…
-
Study raised concerns SARS-CoV-2 evolution outpaces vaccine-generated antibodies
On Apr. 27, 2023, a National Institute of Allergy and Infectious Diseases (NIAID) -led Phase 2 trial compared two…
-
Antibiotics do not cut death risk in hospitalized patients with viral respiratory illnesses
On Mar. 24. 2023, antibiotics do not reduce the risk of dying in adults hospitalized with COVID-19, the…
-
Roche launched next-generation portfolio of SARS-CoV-2 rapid antigen tests
On Oct. 11, 2022, Roche announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for…
-
First gene therapy for adults with severe hemophilia A, BioMarin’s ROCTAVIAN, approved by EC
On Aug. 24, 2022, BioMarin Pharmaceutical announced that the European Commission (EC) has granted conditional marketing authorization (CMA)…
-
COVID-19 | Infectious Disease | NIH | Therapeutics | Vaccine
Vaccine-induced immune response to Omicron wanes substantially over time
On Jul. 19, 2022, the National Institutes of Health (NIH) announced that although COVID-19 booster vaccinations in adults…
-
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Jul. 13, 2022, Moderna announced it has now demonstrated significantly higher antibody titers against all tested variants,…
-
COVID-19 vaccination activates antibodies targeting parts of virus spike protein shared between coronaviruses
On Jul. 5, 2022, Tgen and Northern Arizona University announced that a research team found that the vaccine…
